You have read all your free articles, to continue reading subscribe to read the rest of this content.
Immunovia has announced results from the PanFAM-1 study, a prospective, multi-center, investigational study, designed to assess the performance of the IMMray PanCan-d test in early detection of pancreatic ductal adenocarcinoma (PDAC) in high-risk populations. The IMMray PanCan-d test met its primAlready a subscriber Login You have read all your free…
The two pharma giants reports data which showed clinical improvement in median radiologic progression-free survival (rPFS) with Lynparza (olaparib) in combination with abiraterone compared to abiraterone monotherapy, a standard of care, in metastatic castration-resistant prostate cancer (mCRPC). Already a subscriber Login You have read all your free articles, to continue…
TG02 has passed the initial planned safety review in the phase Ib clinical mechanism-of-action trial evaluating TG02, and TG02 in combination with the checkpoint inhibitor KEYTRUDA (pembrolizumab), in patients with confirmed RAS-mutated colorectal cancer. The safety review was carried out on the Already a subscriber Login You have read all…
BioInvent International announces that the FDA has completed the safety review of its Investigational New Drug (IND) application and have concluded that the proposed pediatric clinical investigation can proceed. The IND application is for a Phase I/IIa study that will evaluate the efficacy and saAlready a subscriber Login You have…
